Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Neurology Rheumatology Diabetes / Metabolic Mental Health / Psychiatry Women's Health Dermatology Men's Health Rare Diseases
Clinical Trial ● Currently Recruiting Non-phase study NCT07135232

The Effects of Resistance Training and a Plant-Based Supplement on Perimenopausal Symptoms and Muscle Health.

The Effects of Resistance Training and a Plant-Based Supplement on Perimenopausal Symptoms and Muscle Health. — Recruiting • Non-phase study • Cardiology / Cardiovascular • NCT07135232.

📅 25 Mar 2026 ⏱ 3 min read
Currently Recruiting
This trial is actively seeking participants in the UK. Discuss eligibility with your patient before referring.
Status
Currently Recruiting
Phase
Non-phase study
NCT ID
NCT07135232
Sponsor
Leeds Beckett University
Start
2026-03-01
ClinicaliQ Trial Snapshot
  • The Effects of Resistance Training and a Plant-Based Supplement on Perimenopausal Symptoms and Muscle Health. — Recruiting • Non-phase study • Cardiology / Cardiovascular • NCT07135232.
  • The aim of this clinical trial is to determine if resistance training and a newly developed plant-based nutritional supplement can improve the symptoms and musculoskeletal health of perimenopausal women. The main questions it aims to evaluate are: 1. Can resistance training and….
  • Sponsor: Leeds Beckett University.

Verify eligibility, endpoints and current status on the original source registry before acting on this summary.

Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

The aim of this clinical trial is to determine if resistance training and a newly developed plant-based nutritional supplement can improve the symptoms and musculoskeletal health of perimenopausal women. The main questions it aims to evaluate are: 1. Can resistance training and the nutritional supplement - both independently and in combination - improve perimenopausal symptoms (e.g. cognition, mood, sleep) and musculoskeletal outcomes (e.g. strength, muscle mass)? 2. What are the acute effects of the nutritional supplement on cognitive function and mood in perimenopausal women, and is this response altered following…

Eligibility Snapshot
  • Perimenopausal women between 40 - 55 years 2. Not currently engaging in consistent structured resistance training (defined as >3 resistance training sessions per week for 4 consecutive weeks, in the past six months). 3. Not on any HRT or hormonal contraception for at least one year before initiation of the study. 4. Able to attend laboratory visits and commit to the intervention schedule for 6 months. 5. Willing to provide blood samples 6. Not regularly consuming any dietary supplements containing concentrated sarmentosin, L-theanine or other compounds that may interfere with the study intervention. 7. Willing to limit dietary intake of Sarmentosin (e.g. Blackcurrant) and L-theanine (e.g. green tea/ black tea). 8. Willing and able to provide written informed consent

Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Guideline
Percutaneous insertion of a catheter-based left ventricular microaxial flow pump for cardiogenic shock
Cardiology / Cardiovascular · 25 Mar 2026
Percutaneous insertion of catheter-based left ventricular microaxial flow pumps may be considered for patients with acute cardiogenic shock refractory to medical therapy…
View guideline →
Guideline
Semaglutide for reducing the risk of major adverse cardiovascular events in people with cardiovascular disease and overweight or obesity
Cardiology / Cardiovascular · 07 May 2026
Semaglutide is recommended for adults with established cardiovascular disease and overweight/obesity to reduce major adverse cardiovascular events – consider prescribing as part…
View guideline →
Guideline
Cardiovascular Disease: Risk Assessment and Reduction (NICE NG238)
Cardiology / Cardiovascular · 27 Mar 2026
Perform CVD risk assessment using Framingham equation or QRISK3 in all adults aged 40–74 years; initiate atorvastatin 20 mg daily if 10-year…
View guideline →
Guideline
Surgical insertion of a catheter-based left ventricular microaxial flow pump for cardiogenic shock
Cardiology / Cardiovascular · 25 Mar 2026
Insert a catheter-based left ventricular microaxial flow pump in patients with acute cardiogenic shock refractory to medical therapy and inotropic support, as…
View guideline →
Clinical Brief
Women’s voices to be at the heart of renewed health strategy
Cardiology / Cardiovascular · NHS England · 14 Apr 2026
Women's Health Strategy will be renewed with enhanced mechanisms to centre female patient voices in healthcare planning and delivery Strategy aims to…
View brief →
Clinical Brief
Weight-loss jabs will be offered on NHS for people at risk of further heart attacks
Cardiology / Cardiovascular · BBC Health · 31 Mar 2026
GLP-1 receptor agonists (weight-loss jabs) will now be offered on NHS to over 1 million people in England at high cardiovascular risk,…
View brief →